Publications by authors named "Cuiping Zhan"
Article Synopsis
- - The study investigates the societal cost-effectiveness of the combination therapy Toliparibizumab with nab-paclitaxel (T+N) for metastatic or recurrent triple-negative breast cancer (TNBC), using clinical data from a randomized trial.
- - Results show that the T+N treatment costs more than the placebo plus nab-paclitaxel (P+N), with incremental cost-effectiveness ratios (ICER) of approximately 1,394,548.41 CNY/QALY for the overall population and 622,663.98 CNY/QALY for the PD-L1 positive subgroup.
- - The analysis suggests that if Toliparibizumab were covered by Chinese medical insurance
Background: In breast cancer (BC), tumor-associated macrophages (TAMs) are an important component of the tumor microenvironment and are closely related to poor prognosis. A growing number of studies have focused on the role of TAMs in BC progression and therapeutic strategies targeting TAMs. As an emerging treatment, the application of nanosized drug delivery systems (NDDSs) in the treatment of BC by targeting TAMs has attracted much attention.
View Article and Find Full Text PDFIdentification of a nine-gene prognostic signature for gastric carcinoma using integrated bioinformatics analyses.
World J Gastrointest Oncol
September 2020
Background: Gastric carcinoma (GC) is one of the most aggressive primary digestive cancers. It has unsatisfactory therapeutic outcomes and is difficult to diagnose early.
Aim: To identify prognostic biomarkers for GC patients using comprehensive bioinformatics analyses.